靶向成纤维细胞激活蛋白放射性药物在恶性肿瘤诊疗中的研究进展

近年来，靶向成纤维细胞激活蛋白（FAP）的放射性药物在恶性肿瘤诊疗一体化领域备受关注。FAP是一种表达于肿瘤间质的蛋白质，在肿瘤进展和转移过程中发挥着重要作用，是肿瘤诊断和治疗的重要靶点。放射性药物通过标记FAP，可以在体内对肿瘤细胞和其周围间质细胞精准靶向，一举实现恶性肿瘤无创可视化诊断和内照射治疗。通过对FAP在肿瘤诊疗中的作用机制、相关放射性药物的研究进展及其临床转化的情况进行综述，并浅析该类放射性药物研究当前存在的挑战以及未来发展的方向，以期为恶性肿瘤的精准诊疗提供新的思路和方法。

Research Progress of Radiopharmaceuticals Targeting Fibroblast Activation Protein in the Diagnosis and Treatment of Malignant Tumors

Fibroblast activation protein (FAP)-targeted radiopharmaceuticals have attracted increasing attention in the integrated diagnosis and treatment of malignant tumors. FAP, a protein expressed in the tumor stroma, plays a pivotal role in tumor progression and metastasis, making it a promising target for tumor treatment. Radiopharmaceuticals targeting FAP have demonstrated their potential to achieve precise targeting of tumor cells and surrounding stromal cells in vivo, thereby enabling non-invasive visualization and internal irradiation therapy of malignant tumors. This article provides a comprehensive review of the mechanism and research progress of FAPrelated radiopharmaceuticals and their clinical translation followed by current challenges and future directions, with the goal of providing innovative ideas and methods for the precise diagnosis and treatment of malignant tumors.